SEC Tracker
Get the app

Viatris VTRS

Viatris to Acquire Pacira for $36.50 per Share

Form
8-K
Filed
Importance
Routine
  1. Agreement to acquire Pacira BioSciences for $36.50 per share in cash
  2. Pacira's products include EXPAREL and ZILRETTA, high-margin U.S. drugs
  3. Transaction expected to close by end of 2026 and be immediately accretive
  4. Viatris plans to expand Pacira's products via its international infrastructure

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Viatris files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Roivant Sciences ROIV public float $9.8B, Sep 30, 2025
  2. United Therapeutics UTHR public float $11.2B, Jun 30, 2025
  3. Neurocrine Biosciences NBIX public float $9.5B, Jun 30, 2025
  4. Exelixis EXEL public float $9.4B, Jul 4, 2025
  5. BIO-TECHNE TECH public float $9.1B, Dec 31, 2025

Data on this page was fetched . The filing on SEC.gov is the record.